Rigel Pharmaceuticals (RIGL) Announces Quarterly Results
Rigel Pharmaceuticals (NASDAQ: RIGL) posted its quarterly earnings results on Tuesday. The company reported ($0.30) EPS for the quarter.
A number of analysts have recently weighed in on RIGL shares. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Rigel Pharmaceuticals in a research note to investors on Friday, December 14th. They now have a $11.00 price target on the stock, down previously from $13.00. On a related note, analysts at Leerink Swann reiterated an “outperform” rating on shares of Rigel Pharmaceuticals in a research note to investors on Friday, December 14th. Finally, analysts at Jefferies Group cut their price target on shares of Rigel Pharmaceuticals to $15.00 in a research note to investors on Thursday, December 13th.
Nine equities research analysts have rated the stock with a buy rating, and three have issued a hold rating to the stock. The company currently has a consensus rating of “overweight” and an average target price of $11.00.
Shares of Rigel Pharmaceuticals (RIGL) opened at 6.82 on Tuesday. Rigel Pharmaceuticals (RIGL) has a 52 week low of $5.37 and a 52 week high of $11.44. The stock’s 50-day moving average is currently $6.7. The company’s market cap is $593.3 million.
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.